首页> 外文OA文献 >Acetyl--carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network

【2h】

Acetyl--carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network

机译：乙酰基肉碱（ALCAR）预防用硼替佐米，阿霉素和小剂量地塞米松治疗的复发或难治性多发性骨髓瘤患者的化疗诱导的周围神经病变：来自威斯康星州肿瘤网络的一项研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Acetyta-carnitine (ALCAM) for the prevention, of .chemotherapy-induced peripheral neuropathy In. patients with" relapsed or refractory multiple myeloma treated with bortezomib, doxorubidn and low-dose dexamethasone: a study from the Wisconsin Oncology Network [J] . Natalie Calender, Stephanie Markovina, Jens Eickhoff, Cancer chemotherapy and pharmacology. . 2014,第4期

机译：乙酰肉碱（ALCAM）用于预防化学疗法引起的周围神经病变In。硼替佐米，阿霉素和小剂量地塞米松治疗的复发或难治性多发性骨髓瘤患者：威斯康星州肿瘤网络的一项研究
2. A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma [J] . Ghobrial Irene M., Liu Chia-Jen, Perez Raymond P., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：新型抗CXCR4抗体Ulocuplumab（BMS-936564）的相IB / II研究与Lenalidomide加低剂量地塞米松，或用Bortezomib加上与复发或难倒多发性骨髓瘤的硼替佐米加上地塞米松
3. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study [J] . Kropff Martin, Vogel Martin, Bisping Guido, Annals of hematology . 2017,第11期

机译：Bortezomib和低剂量地塞米松，有或没有连续的低剂量口服环磷酰胺用于初级耐火或复发多发性骨髓瘤：随机期III研究
4. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
5. Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network [O] . Natalie Callander, Stephanie Markovina, Jens Eickhoff, -1

机译：乙酰左旋肉碱（ALCAR）预防用硼替佐米阿霉素和小剂量地塞米松治疗的复发或难治性多发性骨髓瘤患者的化疗诱发的周围神经病变：来自威斯康星州肿瘤学网络的研究
6. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma [O] . J R Berenson, O Yellin, T Kazamel, 2012

机译：用于复发/难治多骨髓瘤的患者的聚乙二醇化脂质体DOXORUBICIN，硼化族，地塞米松和Lenalidomide的2阶段研究

Acetyl--carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network

著录项

相似文献

相关主题

期刊订阅